Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
drugs
3
×
fda
3
×
life sciences
national blog main
amgen
biotech
boston blog main
boston top stories
calcitonin gene-related peptide
eli lilly
indiana blog main
indiana top stories
migraine
teva pharmaceutical
acute hepatic porphyrias
akin akinc
alder biopharmaceutical
allergan
alnylam pharmaceuticals
american academy of neurology
aminolevulinic acid
atogepant
biohaven
bob azelby
boston
botox
boulder/denver blog main
boulder/denver top stories
brian abrahams
chronic migraine
detroit blog main
detroit top stories
episodic migraine
eptinezumab
erenumab
fremanezumab
galcanezumab
givosiran
impel neuropharma
What
approval
3
×
drug
fda
class
migraine
new
won
ago
alnylam
announced
approved
arguments
big
commercialized
companies
competitors
decades
decision
developed
drugs
eli
headache
indicated
interference
late
lilly
make
marks
medicine
medicines
meeting
neuro
nod
oral
pain
pharmaceuticals
potential
prevent
quick
rna
Language
Current search:
fda
×
drugs
×
approval
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines